Latest News and Press Releases

HEALOS trial did not meet primary efficacy endpoint  in overall study population Clinically and statistically significant improvement in subpopulation of patients with profound acute hearing...

Auris Medical to Report Third Quarter 2017 Financial Results and Provide Business Update on Tuesday, November 28, 2017 Zug, Switzerland, November 21, 2017 - Auris Medical Holding AG (NASDAQ:...

Zug, Switzerland, October 11, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Zug, Switzerland, September 28, 2017 - Auris Medical Holding AG (the "Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical...

Zug, Switzerland, September 26, 2017 - Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

Trial now includes more than 730 patients under previously announced amended protocol Top-line results from TACTT3 expected in first quarter 2018 Zug, Switzerland, September 22, 2017 - Auris...

ZUG, Switzerland, Sept. 20, 2017 -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in...

ZUG, Switzerland, Sept. 5, 2017 (GLOBE NEWSWIRE) -- Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...

Zug, Switzerland, August 24, 2017 - Auris Medical Holding AG ("the Company", NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs...

Phase 3 results from AM-111 HEALOS trial expected in fourth quarter 2017 Phase 3 results from Keyzilen® TACTT3 trial expected in first quarter 2018 Conference call set for 8 am EDT (2 pm CEST)...